UPDATES: NCCN Guidelines® and NCCN Compendium®
NCCN Flash Update sent March 20, 2014
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer. These NCCN Guidelines® are currently available as Version 2.2014.
- The following references were added to Acceptable Recurrence Therapies: (OV-D 2 of 2):
- Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25:5165-5171.
- Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25:5180-5186.
- The Discussion section has been updated to reflect the changes in the algorithm.
*For your reference, the announcement of the previous update (Version 1.2014) to the NCCN Guidelines for Ovarian Cancer, distributed on February 7, 2014, is included below:
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Ovarian Cancer. These NCCN Guidelines® are currently available as Version 1.2014.
- Epithelial Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer
- As part of the workup, a referral for genetic risk evaluation is now recommended for all patients. A corresponding footnote was added that states, “Primary treatment should not be delayed for a genetic counseling session.” (OV-1)
- For stage II, III, IV post-primary treatment, the use of postremission paclitaxel as a secondary adjuvant therapy was changed from a category 2B recommendation to a category 3 recommendation. (OV-4)
- Principles of Surgery (OV-A)
- Significant revisions were made to this section.
- Principles of Chemotherapy
- Prior to the initiation of any therapy, it is recommended that, “Patients of child-bearing potential who desire fertility-sparing procedures should be referred to an appropriate fertility specialist.” (OV-B 1 of 3)
- Two sections were added (OV-B 2 of 3):
- For elderly patients (>age 65) and/or those with comorbidities
- Definitions used in the NCCN Guidelines for Ovarian Cancer
- Primary Chemotherapy/Primary Adjuvant Therapy Regimens for Stage II-IV (OV-B 3 of 3)
- This section was moved to the Principles of Chemotherapy and reorganized to designate intraperitoneal (IP)/intravenous (IV) regimens and IV regimens.
- Footnote “2” was added stating, “IV regimens may be considered for neoadjuvant therapy.”
- Acceptable Recurrence Therapies (OV-D 1 of 2)
- Single agent doxorubicin was added to the list of other potentially active, cytotoxic therapies.
- Less Common Ovarian Histopathologies
- Malignant Germ Cell Tumors (LCOH-3)
- Footnote “d” was added to clarify that, “Pediatric/young adult patients with the following clinical presentations may consider observation or chemotherapy as treatment options: Stage IA, IB dysgerminoma; stage IA, grade 1 immature teratoma; stage IA embryonal tumors; or stage IA yolk sac tumors.”
- Ovarian Low Malignant Potential Tumors (Borderline Epithelial Ovarian Tumors) (LCOH-6)
- This section was moved to Less Common Ovarian Histopathologies.
- Footnote “n” was added stating, “Chemotherapy (IV or IP) has not been shown to be beneficial in ovarian low malignant potential tumors (borderline epithelial ovarian tumors).”
- Staging (ST-1- ST-4)
- A link was added for the newly updated FIGO staging guidelines while the AJCC staging manual update is currently in progress.
For the complete updated versions of the NCCN Guidelines, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), and the NCCN Chemotherapy Order Templates (NCCN Templates®), please visit NCCN.org.
To access the NCCN Biomarkers Compendium™, please visit NCCN.org/biomarkers.
To view the NCCN Guidelines for Patients®, please visit NCCN.org/patients.
Free NCCN Guidelines apps iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps